tiprankstipranks
Trending News
More News >
Meihua International Medical Technologies Co., Ltd. (MHUA)
NASDAQ:MHUA
US Market
Advertisement

Meihua International Medical Technologies Co., Ltd. (MHUA) AI Stock Analysis

Compare
43 Followers

Top Page

MHUA

Meihua International Medical Technologies Co., Ltd.

(NASDAQ:MHUA)

Select Model
Select Model
Select Model
Neutral 68 (OpenAI - 4o)
Rating:68Neutral
Price Target:
$0.50
▲(28.21% Upside)
Meihua International Medical Technologies Co., Ltd. has a strong financial foundation with low leverage and stable revenue, contributing significantly to its score. The valuation is attractive due to a low P/E ratio, indicating potential undervaluation. Technical analysis presents a neutral outlook with weak momentum. The absence of earnings call and corporate events data limits further insights.

Meihua International Medical Technologies Co., Ltd. (MHUA) vs. SPDR S&P 500 ETF (SPY)

Meihua International Medical Technologies Co., Ltd. Business Overview & Revenue Model

Company DescriptionMeihua International Medical Technologies Co., Ltd. engages in the manufacture and marketing of medical consumables in the People's Republic of China. It offers class I, II, and III disposable medical devices. The company's products include non-bottled products, such as brushes and ID bracelets; and polyethylene bottled products, such as eye drop and tablet bottles. It also distributes disposable medical devices sourced from other manufacturers to customers in China. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China. Meihua International Medical Technologies Co., Ltd. operates as a subsidiary of Bright Accomplish Limited.
How the Company Makes MoneyMeihua International Medical Technologies Co., Ltd. generates revenue through the sale of its medical products to healthcare institutions and distributors. Its key revenue streams include direct sales to hospitals and clinics, as well as partnerships with medical supply distributors who help expand its market reach. The company benefits from a strong network of distribution channels that facilitate the delivery of its products to a wide range of customers. Additionally, Meihua may engage in strategic collaborations with other healthcare companies to enhance its product offerings and market presence, thereby contributing to its earnings.

Meihua International Medical Technologies Co., Ltd. Financial Statement Overview

Summary
Meihua International Medical Technologies Co., Ltd. demonstrates solid financial health with stable revenue and robust operating performance. While leverage is low, enhancing financial resilience, the company faces challenges in maintaining consistent free cash flow.
Income Statement
75
Positive
The company has demonstrated consistent revenue generation with slight fluctuations. Gross profit margins remain stable, indicating efficient production or service delivery. However, net profit margins have declined, suggesting increased costs or lower efficiency in managing expenses. The EBIT and EBITDA margins are robust, reflecting strong operating performance.
Balance Sheet
70
Positive
The balance sheet shows a strong equity position with a favorable debt-to-equity ratio, indicating low leverage and financial stability. The return on equity has been positive, suggesting effective use of shareholder funds. However, the equity ratio has seen minor variations, reflecting changes in asset management.
Cash Flow
65
Positive
The cash flow statement reveals a significant improvement in operating cash flows in recent years, enhancing liquidity. Despite this, free cash flow has been volatile, occasionally negative, indicating challenges in managing capital expenditures and cash generation relative to net income.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue96.91M97.10M103.35M104.04M89.06M
Gross Profit33.30M33.10M38.10M39.81M37.16M
EBITDA15.70M15.77M16.12M26.88M23.99M
Net Income10.84M11.63M6.24M20.95M19.05M
Balance Sheet
Total Assets186.24M171.92M163.58M136.86M106.05M
Cash, Cash Equivalents and Short-Term Investments15.96M16.93M26.74M8.15M7.19M
Total Debt7.95M7.33M6.81M5.18M3.22M
Total Liabilities27.26M25.08M24.90M30.05M21.31M
Stockholders Equity158.98M146.33M138.12M106.81M84.74M
Cash Flow
Free Cash Flow14.50M-2.41M-11.86M-904.89K-10.79M
Operating Cash Flow14.64M2.28M-9.16M-54.66K5.33M
Investing Cash Flow-20.42M-12.46M-8.62M-833.82K-16.09M
Financing Cash Flow6.21M706.13K37.25M1.86M1.71M

Meihua International Medical Technologies Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.39
Price Trends
50DMA
0.40
Negative
100DMA
0.41
Negative
200DMA
0.37
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
40.78
Neutral
STOCH
10.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MHUA, the sentiment is Negative. The current price of 0.39 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.40, and above the 200-day MA of 0.37, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.78 is Neutral, neither overbought nor oversold. The STOCH value of 10.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MHUA.

Meihua International Medical Technologies Co., Ltd. Risk Analysis

Meihua International Medical Technologies Co., Ltd. disclosed 80 risk factors in its most recent earnings report. Meihua International Medical Technologies Co., Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Meihua International Medical Technologies Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$12.76M1.265.90%-4.99%-19.11%
52
Neutral
13.20M-0.77-89.16%-19.32%44.73%
51
Neutral
25.03M-2.79-11.43%-0.24%50.45%
49
Neutral
19.77M-0.34-364.88%-12.24%-427.45%
44
Neutral
8.86M-0.556022.04%-38.79%58.27%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MHUA
Meihua International Medical Technologies Co., Ltd.
0.37
-0.67
-64.42%
HBIO
Harvard Bioscience
0.44
-2.28
-83.82%
RVP
Retractable Technologies
0.84
0.08
10.53%
EKSO
EKSO BIONICS
5.06
-12.94
-71.89%
POAI
Predictive Oncology
0.78
-0.01
-1.27%
STSS
Sharps Technology, Inc.
6.72
-1,078.32
-99.38%

Meihua International Medical Technologies Co., Ltd. Corporate Events

Leadership Changes at Meihua International Medical Technologies
Aug 21, 2025

On August 15, 2025, Meihua International Medical Technologies Co., Ltd. announced significant changes in its leadership team, with the resignation of CEO Xin Wang, CFO Lianzhang Zhao, and board member Huijuan Zhao, all citing personal reasons. The company appointed Leyi Lee as the new CEO, Shilong Liao as the new CFO, and Anna Colin as an independent director, signaling a strategic shift in leadership. These appointments are expected to bring new perspectives and expertise to the company, potentially impacting its strategic direction and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 21, 2025